Research programme: sickle cell anaemia therapeutics - Bayer/Children's Hospital and Research Center Oakland
Latest Information Update: 16 Jul 2016
At a glance
- Originator Bayer HealthCare; Childrens Hospital of Oakland
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Sickle-cell-anaemia in USA
- 08 Mar 2013 Early research in Sickle cell anaemia in USA (unspecified route)